Fresenius Medical Care Publishes Global Study On Hemodiafiltration Associated With Lower Relative Risk Of Death From Conventional High-Flux Hemodialysis
Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with kidney diseases, today announced the publication of a large international study reporting that
Fresenius Medical Care published research showing their hemodiafiltration treatment may help kidney patients live longer than a common alternative treatment. This kind of positive research can make people more confident in the company's products, though real-world results take time to prove.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.